SION
Sionna Therapeutics, Inc. · Healthcare
36.16
3.28%(-1.23)
Market OpenLast Updated: — ET
52W L: $7.2552W H: $45.00
$35.94
CHG+2.94 (+8.92%)
H$42.59
L$33.00
VOL5.2M
SION (1h)
Sionna Therapeutics, Inc. · Healthcare
WALTHAM, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in one-on-one investor meetings at the Raymond James 2026 Biotech Innovation Symposium on Tuesday, April 14th, 2026.
Jennifer Fitzpatrick sold 10,250 shares for a total of approximately $347,000 on March 5, 2026. This transaction represented 100.00% of her direct common stock holdings, reducing direct ownership of common stock to zero.
Superstring Capital Management acquired 180,593 shares of Sionna Therapeutics in the fourth quarter. The quarter-end position value rose by $7.43 million, reflecting the purchase of a new position.
OrbiMed Advisors sold 143,304 shares of Sionna Therapeutics in the fourth quarter; the estimated transaction value was $5.43 million based on quarterly average prices. Meanwhile, the quarter-end position value increased by $37.56 million, reflecting both trading and stock price movement.
Ongoing PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis is on track with topline data anticipated in mid-2026 Ongoing Phase 1 trial evaluating NBD1 stabilizer SION-451 in proprietary dual combinations with SION-2222 and with SION-109 in healthy volunteers is on track with topline data anticipated in mid-2026 Maintained strong cash position with approximately $310.3 million in cash and cash equivalents, expected to fund operations into 2028 WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.
WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in fireside chats at the following upcoming investor events:
Fitzpatrick Jennifer
officer: Chief Legal Officer
10,250 SH @ $6.11
2026-03-05
Fitzpatrick Jennifer
officer: Chief Legal Officer
10,250 SH @ $6.11
2026-03-05
Fitzpatrick Jennifer
officer: Chief Legal Officer
10,250 SH @ $33.86
2026-03-05
Thompson Peter A.
director
1,890 SH @ $44.57
2026-02-02
Thompson Peter A.
director
29,063 SH @ $44.58
2026-02-03
ORBIMED ADVISORS LLC
director
1,890 SH @ $44.57
2026-02-02
ORBIMED ADVISORS LLC
director
29,063 SH @ $44.58
2026-02-03
TPG GP A, LLC
10 percent owner
250,000 SH @ $40.00
2026-01-22